Agoracom Blog Home

Posts Tagged ‘clinicaltrials’

VIDEO – Empower Clinics Comes Out Of Stealth Mode With Big Growth And A Grand Plan To Restore Shareholder Value

Posted by Paul Nanuwa at 6:46 PM on Friday, April 5th, 2024

Empower Clinics is a healthcare company with a growing research and clinical trials division that is currently achieving early success in the Dallas and Los Angeles markets, including already being awarded its first clinical trial from a Global Fortune 500 Pharmaceutical Company.

But Empower is just getting started according to CEO Steven McAuley, who has come out of regulator mandated stealth mode to report very promising business growth to shareholders.

Specifically, while under cease trade, Empower has grown their active sites from 2 in the fall to 6 today – and Principal Investigators from 6 to 14 today.  That foundation of doctors and medical offices opens the door to potential major contract wins from pharmaceutical companies that need speed and smarts from partners like Empower to get their clinical trials completed.

Empower’s timing couldn’t be better because Fortune Business Insights states the global Clinical Trials Market size is projected to reach USD 92.45 billion in 2030, driven by expanding pharmaceutical, biotechnology, and medical device R&D pipelines as developed G20 nations demographics get increasingly older.  This positions Empower to play a pivotal role  in this transformative era of healthcare.

Watch this powerful interview with CEO Steven McAuley and AGORACOM Founder George Tsiolis.

EMPOWER CLINICS ANNOUNCES AWARD OF FIRST CLINICAL TRIAL FROM GLOBAL FORTUNE 500 PHARMACEUTICAL COMPANY

Posted by Aidi Munoz at 9:40 AM on Tuesday, September 26th, 2023

Empower Clinics Inc (EPW: CSE) (EPWCF: PINK), a leading healthcare company, is proud to announce a significant milestone in its research and clinical trials division. Its subsidiary, EPW Curesearch LLC (“EPWC”), has successfully secured its inaugural clinical trial from a major European pharmaceutical powerhouse with a staggering market capitalization exceeding $100 billion. This monumental achievement is set to impact the future of healthcare outcomes worldwide.

Building upon its previous announcement on July 31, 2023, which highlighted multiple study applications covering diverse disease states, Empower Clinics confirms that this awarded clinical trial will be dedicated to addressing Chronic Obstructive Pulmonary Disease (COPD). The trial will be spearheaded by one of the company’s most seasoned Principal Investigators (PIs).

The collaboration between Empower Clinics, their PI, and the pharmaceutical sponsor is poised to enroll between 20 to 35 patients, primarily from the existing patient roster, with the recruitment window extending into mid-2024 and the possibility of extensions. Remarkably, there are no restrictions on the maximum number of patients per site, enabling EPWC to source additional participants from external medical centers, hospitals, and various social recruitment channels, including Facebook, Instagram, Twitter, and other digital marketing avenues.

Steven McAuley, Chairman & CEO of Empower Clinics, expressed his enthusiasm, stating, “We are all ecstatic to receive our first awarded clinical trial, a result of consistent and persistent effort over the past number of months. Our focus on partnering with large established medical centers and very experienced medical doctors has proven successful.” He further anticipates additional sponsor due diligence, site visits, and awards in the future.

Empower Clinics has strategically aligned itself with practicing medical doctors, who are specialists in their respective fields and have previous research and clinical trials experience. These PIs play a pivotal role in the success of Empower’s Site Management Organization (SMO), facilitating meaningful revenues from the Biotech and Pharmaceutical industries, providing oversight and support to patients, and acting as a crucial liaison between pharmaceutical companies and Contract Research Organizations (CROs).

While the company continues to navigate through a Cease Trade Order and accounting and audit procedures, the enormous market opportunity beckons. The Clinical Research Organization (CRO) Services Market is set to reach $127.3 billion by 2028, driven by the ever-expanding pharmaceutical, biotechnology, and medical device R&D pipelines, as well as advancements in clinical trial processes. Empower Clinics is positioned to play a pivotal role in this transformative era of healthcare.

About Empower:

Empower is a patient-focused healthcare company committed to making a positive impact on lives and future healthcare outcomes through clinical trials. With two clinical research sites and six principal investigators, Empower operates as a Site Management Organization (SMO) with multiple clinical trials in the pipeline. Additionally, the company has announced its intention to create a healthcare AI spinout focused on enhancing patient identification, recruitment, and onboarding for clinical trials.

Read release: https://www.einpresswire.com/article/657704521/empower-clinics-announces-award-of-first-clinical-trial-from-global-fortune-500-pharmaceutical-company